Reference
Thomas M, et al. Was the Evidence Base for Yescarta and Kymriah Sufficient to Justify their Cost and Secure Patient Access Across 5 Markets? 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PDG79, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3121/97788
Rights and permissions
About this article
Cite this article
Restricted access to CAR-T cell therapies due to uncertainty. PharmacoEcon Outcomes News 842, 24 (2019). https://doi.org/10.1007/s40274-019-6416-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6416-2